{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:03:45Z","timestamp":1784099025686,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is a priority and important treatment for EGFR-mutated non-small cell lung cancer (NSCLC) and significantly improves patient\u2019s survival. However, these patients eventually develop disease progression due to acquired resistance to EGFR-TKI. Mesenchymal epithelial transition (MET) gene alteration is one of the common EGFR-independent mechanisms to resist EGFR-TKI. This study reports that a case with chief complaint of dry cough for six months was diagnosed with right lung adenocarcinoma (cT4N3M1c, stage IVB). After first-generation EGFR-TKI treatment, the patient underwent disease progression. After a multi-disciplinary team (MDT) discussion, a re-biopsy and next-generation sequencing (NGS) profiling were performed again, which indicated that the patient harbored the EGFR exon21 L858R mutation and the exon20 T790M mutation. According to the MDT discussion, the patient received the third-generation EGFR-TKI treatment and stereotactic body radiation therapy (SBRT), achieving long-term survival with a high quality of life. After three years of the third-generation EGFR-TKI treatment, the disease progressed again, and a biopsy indicated multiple mutations. After disease progression during the third-generation EGFR-TKI treatment and radiotherapy, the patient received combined treatment with first-generation and the third-generation EGFR-TKI, but could not tolerate the combined treatment. After three courses of chemotherapy plus bevacizumab targeted therapy, the disease continued to progress. Without other effective treatments, the patient received dual-targeted therapy with the third-generation EGFR-TKI and MET-TKI for one month, and the patient experienced a reduction of 51.4% in the size of the lesions in the chest. Unfortunately, the patient developed a lung infection and died of a lung infection. With the assistance of MDT recommendations, the patient received comprehensive treatment and remained asymptomatic, with persistent improvement in the quality of life for 4 years. The overall survival was approximately 56.5 months. Patients with metastatic EGFR-mutated NECLC require multidisciplinary discussions and comprehensive treatment. When the disease progresses, rebiopsy and NGS profiling are required to identify sensitive targeted drugs. Whether MET overexpression is a mechanism for the resistance to third-generation EGFR-TKI in NSCLC patients with EGFR mutations remains to be further investigated.<\/jats:p>","DOI":"10.3389\/fonc.2026.1836074","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:41Z","timestamp":1784095481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Short-term response to mesenchymal epithelial transition inhibitor\/epidermal growth factor receptor tyrosine kinase inhibitor combination in EGFR-mutated non-small cell lung cancer with acquired MET overexpression after progression and discussion on comprehensive management"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaofeng","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Second Affiliated Hospital, National Ministry of Education Key Laboratory of Cancer Prevention and Intervention, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Conservative Dentistry and Endodontics, Saraswati Dental College","place":["Lucknow, Uttar Pradesh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Texila American University","place":["Georgetown, Guyana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzheng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Second Affiliated Hospital, National Ministry of Education Key Laboratory of Cancer Prevention and Intervention, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Taizhou Cancer Hospital","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Chao","family":"Qin","sequence":"additional","affiliation":[{"name":"Oncology Internal Medicine Treatment Unit, Guangyuan Traditional Chinese Medicine Hospital Affiliated to Chengdu University of Traditional Chinese Medicine","place":["Guangyuan, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the C-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11864-020-0723-5","article-title":"Management of non-small cell lung cancer patients with Met exon 14 skipping mutations","volume":"21","author":"Huang","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.413","article-title":"Oa02.03 the third generation EGFR inhibitor (EGFR-TKI) HS-10296 in advanced NSCLC patients with resistance to first generation EGFR-TKI","volume":"14","author":"Lu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.06.017","article-title":"Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance","volume":"12","author":"Wang","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.60.7317","article-title":"Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer","volume":"33","author":"Scagliotti","year":"2015","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241264730","article-title":"A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with Met overexpression treated with gumarontinib","volume":"16","author":"Yu","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.01.006","article-title":"Survival outcomes among lung cancer patients treated using a multidisciplinary team approach","volume":"19","author":"Bilfinger","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.lungcan.2018.07.032","article-title":"Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study","volume":"124","author":"Stone","year":"2018","journal-title":"Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12890-025-03569-1","article-title":"Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs","volume":"25","author":"Kuang","year":"2025","journal-title":"BMC Pulm Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: The constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32809","article-title":"Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer","volume":"126","author":"Lee","year":"2020","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.09.019","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study","volume":"137","author":"Mehlman","year":"2019","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03239-1","article-title":"Acquired resistance to osimertinib in patients with non-small-cell lung cancer: Mechanisms and clinical outcomes","volume":"146","author":"Mu","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40265-018-0916-4","article-title":"Targeting EGFR in lung cancer: Current standards and developments","volume":"78","author":"D\u00edaz-Serrano","year":"2018","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4062\/biomolther.2021.047","article-title":"Chronicles of EGFR tyrosine kinase inhibitors: Targeting EGFR C797S containing triple mutations","volume":"30","author":"Duggirala","year":"2022","journal-title":"Biomol Ther (Seoul)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.10.021","article-title":"Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib","volume":"141","author":"Zhao","year":"2020","journal-title":"Lung Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"Met inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.163843","article-title":"A comparison of consistency of detecting C-Met gene amplification in peripheral blood and tumor tissue of nonsmall cell lung cancer patients","volume":"11","author":"Chen","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with Met overexpression or Met amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): An open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-17-0368","article-title":"Preclinical evaluation of SCC244 (glumetinib), a novel, potent, and highly selective inhibitor of C-Met in Met-dependent cancer models","volume":"17","author":"Ai","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S388846","article-title":"Effect of food on the pharmacokinetics and safety of a novel C-Met inhibitor SCC244: A randomized phase I study in healthy subjects","volume":"17","author":"Wu","year":"2023","journal-title":"Drug Des Devel Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1836074\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:04:46Z","timestamp":1784095486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1836074\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1836074"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1836074","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1836074"}}